IIHG offers pharmacogenetic testing
Thursday, October 17, 2013
A key area of clinical importance in the field of human genetics is that of gene-drug interactions, commonly called Pharmacogenomics (PGx). Several gene-drug pairs affecting drug metabolism and transport have been identified. In fact the FDA currently suggests genetic testing for 10% of all drugs. The most well-studied and validated of these genes are the Cytochrome P450 (CYP) enzymes, which have a role in the metabolism of a large number of drugs. Identifying a patient’s DNA profile for these genes can help determine which drugs at what dose are the most effective and cause the fewest side-effects. The IIHG is currently offering a genetic screen for one of these genes, CYP2C19 for people taking clopidogrel (Plavix®).
CYP2C19 for Clopidogrel Efficacy
The IIHG is offering a pharmacogenetic test for patient response to clopidogrel (Plavix®), a blood thinner commonly prescribed after patients receive percutaneous coronary intervention (PCI) such as stents or angioplasty. The test involves determining four variants in the gene CYP2C19 that have been determined to affect clopidogrel metabolism. More information for patients or health care providers can be found below.
Story Source: Iowa Institute of Human Genetics, 2114 Westlawn, 200 Newton Road, Iowa City, Iowa 52242